Oryzon Genomics SA (ORYZF)
3.645
-0.06
(-1.49%)
USD |
OTCM |
Jun 10, 16:00
Oryzon Genomics Shareholders Equity (Quarterly) : 120.20M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 120.20M |
| December 31, 2025 | 123.84M |
| September 30, 2025 | 124.02M |
| June 30, 2025 | 125.55M |
| March 31, 2025 | 84.44M |
| December 31, 2024 | 83.88M |
| September 30, 2024 | 88.62M |
| June 30, 2024 | 85.12M |
| March 31, 2024 | 81.80M |
| December 31, 2023 | 82.97M |
| September 30, 2023 | 76.86M |
| June 30, 2023 | 78.56M |
| March 31, 2023 | 75.25M |
| December 31, 2022 | 70.89M |
| September 30, 2022 | 63.60M |
| June 30, 2022 | 67.46M |
| March 31, 2022 | 71.42M |
| December 31, 2021 | |
| September 30, 2021 | 84.92M |
| June 30, 2021 | 82.41M |
| March 31, 2021 | 80.75M |
| Date | Value |
|---|---|
| December 31, 2020 | 86.29M |
| September 30, 2020 | 84.03M |
| June 30, 2020 | 81.46M |
| March 31, 2020 | 60.14M |
| December 31, 2019 | 62.82M |
| September 30, 2019 | 62.05M |
| June 30, 2019 | 45.10M |
| March 31, 2019 | 43.50M |
| December 31, 2018 | 45.67M |
| September 30, 2018 | 33.40M |
| June 30, 2018 | 34.72M |
| March 31, 2018 | 34.63M |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | 24.91M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Pharma Mar SA | 287.67M |
| Grifols SA | 6.289B |
| ACADIA Pharmaceuticals, Inc. | 1.248B |
| Alkermes Plc | 1.752B |
| Alnylam Pharmaceuticals, Inc. | 1.075B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 163.27M |
| Total Liabilities (Quarterly) | 26.97M |
| Debt to Equity Ratio | 0.0681 |
| Current Ratio | 1.834 |
| Net Debt Paydown Yield | 0.66% |